Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen’s KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Oncology Breakthrough | Verastem's FDA-approved Av-Fak for KRAS-mutant LGSOC marks its transition to a commercial-stage company, positioning it as a key player in targeted cancer therapies |
Market Access Strategy | Pursuit of NCCN guideline listing could expand Av-Fak's reach beyond KRAS-mutant LGSOC, potentially eliminating KRAS testing requirements and boosting adoption rates |
Pipeline Potential | VS-7375, targeting KRAS G12D mutation, shows promise in expanding Verastem's oncology portfolio beyond LGSOC, with Phase I data eagerly anticipated at upcoming ASCO meeting |
Financial Outlook | Analysts set $16 price target, reflecting optimism despite -$131M EBITDA. Strong liquidity position with 3.5 current ratio supports growth initiatives and pipeline development |
Metrics to compare | VSTM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVSTMPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.1x | −3.4x | −0.5x | |
PEG Ratio | −0.12 | −0.17 | 0.00 | |
Price/Book | −9.7x | 2.1x | 2.6x | |
Price / LTM Sales | 31.4x | 10.0x | 3.3x | |
Upside (Analyst Target) | 134.5% | 66.9% | 42.8% | |
Fair Value Upside | Unlock | 10.6% | 6.5% | Unlock |